CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
51.76
+2.06 (4.14%)
At close: Apr 8, 2026, 4:00 PM EDT
51.36
-0.40 (-0.77%)
After-hours: Apr 8, 2026, 7:56 PM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $70.29, which forecasts a 35.80% increase in the stock price over the next year. The lowest target is $44 and the highest is $110.
Price Target: $70.29 (+35.80%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 7 | 7 | 7 | 7 | 6 | 6 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 20 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $105 → $110 | Buy | Reiterates | $105 → $110 | +112.52% | Mar 17, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $74 → $76 | Strong Buy | Maintains | $74 → $76 | +46.83% | Feb 17, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $40 → $45 | Hold | Maintains | $40 → $45 | -13.06% | Feb 13, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $62 → $74 | Buy | Maintains | $62 → $74 | +42.97% | Feb 13, 2026 |
| Needham | Needham | Strong Buy Maintains $80 → $82 | Strong Buy | Maintains | $80 → $82 | +58.42% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
29.61M
from 3.51M
Increased by 743.50%
Revenue Next Year
77.93M
from 29.61M
Increased by 163.21%
EPS This Year
-5.02
from -6.47
EPS Next Year
-4.16
from -5.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 106.1M | 264.1M | |||
| Avg | 29.6M | 77.9M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2,921.4% | 792.0% | |||
| Avg | 743.5% | 163.2% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.42 | -0.65 | |||
| Avg | -5.02 | -4.16 | |||
| Low | -6.70 | -6.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.